• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and man.

作者信息

Assandri A, Buniva G, Martinelli E, Perazzi A, Zerilli L

出版信息

Adv Exp Med Biol. 1984;171:9-23.

PMID:6372406
Abstract
摘要

相似文献

1
Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and man.地夫可特在大鼠、狗、猴和人体内的药代动力学与代谢。
Adv Exp Med Biol. 1984;171:9-23.
2
Disposition of a new steroidal anti-inflammatory agent, deflazacort, in rat, dog and man.一种新型甾体抗炎药地夫可特在大鼠、狗和人体中的处置情况。
Eur J Drug Metab Pharmacokinet. 1980;5(4):207-15. doi: 10.1007/BF03189466.
3
Disposition and metabolism of a new steroidal anti-inflammatory agent, deflazacort, in cynomolgus monkeys.新型甾体抗炎药地夫可特在食蟹猴体内的处置与代谢
Xenobiotica. 1983 Mar;13(3):185-96. doi: 10.3109/00498258309052253.
4
Pharmacokinetics of nimodipine. I. Communication: absorption, concentration in plasma and excretion after single administration of [14C]nimodipine in rat, dog and monkey.尼莫地平的药代动力学。I. 通讯：大鼠、狗和猴单次给予[14C]尼莫地平后的吸收、血浆浓度及排泄
Arzneimittelforschung. 1985;35(12):1781-6.
5
Pharmacokinetic properties of TDP4815 after single intravenous and oral administrations to rat, rabbit, monkey, dog and in vitro drug metabolism.TDP4815在大鼠、兔、猴、犬单次静脉注射和口服给药后的药代动力学特性及体外药物代谢。
Biopharm Drug Dispos. 2008 Apr;29(3):127-38. doi: 10.1002/bdd.592.
6
[Biochemical studies with oxitropium bromide. 1. Pharmacokinetics and metabolism in the rat and dog].[溴化氧托品的生化研究。1. 大鼠和犬体内的药代动力学与代谢]
Arzneimittelforschung. 1985;35(1A):255-65.
7
Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.达沙替尼（BMS-354825）的临床前药代动力学及体外代谢：一种针对SRC和BCR-ABL的强效口服多靶点激酶抑制剂
Cancer Chemother Pharmacol. 2008 Mar;61(3):365-76. doi: 10.1007/s00280-007-0478-8. Epub 2007 Apr 11.
8
Pharmacokinetics and metabolism of the anti-inflammatory agent Voltaren.
Scand J Rheumatol Suppl. 1978(22):17-29. doi: 10.3109/03009747809097212.
9
Pharmacokinetics of nisoldipine. I. Absorption, concentration in plasma, and excretion after single administration of [14C]nisoldipine in rats, dogs, monkey, and swine.尼索地平的药代动力学。I. 大鼠、狗、猴和猪单次给予[14C]尼索地平后的吸收、血浆浓度及排泄
Arzneimittelforschung. 1988 Aug;38(8):1093-8.
10
Disposition of alpha-[(dimethylamino)methyl]-2-(3-ethyl-5-methyl-4-isoxazolyl)- 1H-indole-3-methanol (59-801), a hypoglycaemic agent in rats, dogs and monkeys.α-[(二甲基氨基)甲基]-2-(3-乙基-5-甲基-4-异恶唑基)-1H-吲哚-3-甲醇（59-801）在大鼠、狗和猴体内的处置，一种降血糖药物。
Xenobiotica. 1987 Jun;17(6):741-9. doi: 10.3109/00498258709043981.

引用本文的文献

1
Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.依类固醇类型、患者年龄和功能状态划分的门诊型杜氏肌营养不良症的疾病进展率。
J Comp Eff Res. 2023 Apr;12(4):e220190. doi: 10.57264/cer-2022-0190. Epub 2023 Feb 7.
2
Functional and Clinical Outcomes Associated with Steroid Treatment among Non-ambulatory Patients with Duchenne Muscular Dystrophy1.非卧床的杜氏肌营养不良症患者接受类固醇治疗的功能和临床结果1 。
J Neuromuscul Dis. 2023;10(1):67-79. doi: 10.3233/JND-221575.
3
Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
比较地夫可特和泼尼松治疗杜氏肌营养不良症。
J Neuromuscul Dis. 2022;9(4):463-476. doi: 10.3233/JND-210776.
4
Expeditious synthesis and preliminary antimicrobial activity of deflazacort and its precursors.地夫可特及其前体的快速合成与初步抗菌活性
RSC Adv. 2019 Jul 10;9(37):21519-21524. doi: 10.1039/c9ra03673c. eCollection 2019 Jul 5.
5
In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.6β-羟基-21-去乙酰基地夫可特（地夫可特的主要人体代谢物）的体外细胞色素 P450 和转运体介导的药物相互作用潜力。
Pharmacol Res Perspect. 2021 Apr;9(2):e00748. doi: 10.1002/prp2.748.
6
Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort.代谢产物 V，一种环氧化物，是在人类单次口服地夫可特后循环中的一种次要代谢产物。
Pharmacol Res Perspect. 2020 Dec;8(6):e00677. doi: 10.1002/prp2.677.
7
Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.地夫可特与泼尼松治疗杜氏肌营养不良症：近期多中心临床试验疾病进展率的荟萃分析。
Muscle Nerve. 2020 Jan;61(1):26-35. doi: 10.1002/mus.26736. Epub 2019 Nov 7.
8
Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis.合成糖皮质激素治疗与下丘脑-垂体-肾上腺轴。
Int J Mol Sci. 2017 Oct 20;18(10):2201. doi: 10.3390/ijms18102201.
9
Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.地夫可特：与其他皮质类固醇相比的治疗指数、相对效价及等效剂量
BMC Pharmacol Toxicol. 2017 Jan 5;18(1):1. doi: 10.1186/s40360-016-0111-8.
10
Deflazacort versus other glucocorticoids: a comparison.地夫可特与其他糖皮质激素的比较
Indian J Dermatol. 2008;53(4):167-70. doi: 10.4103/0019-5154.44786.